Crossref journal-article
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences (341)
Abstract

The unrestrained growth of tumor cells is generally attributed to mutations in essential growth control genes, but tumor cells are also influenced by signals from the environment. In multiple myeloma (MM), the factors and signals coming from the bone marrow microenvironment are possibly even essential for the growth of the tumor cells. As targets for intervention, these signals may be equally important as mutated oncogenes. Given their oncogenic potential, WNT signals form a class of paracrine growth factors that could act to influence MM cell growth. In this paper, we report that MM cells have hallmarks of active WNT signaling, whereas the cells have not undergone detectable mutations in WNT signaling genes such asadenomatous polyposis coliand β-catenin(CTNNB1). We show that the malignant MM plasma cells overexpress β-catenin, including its N-terminally unphosphorylated form, suggesting active β-catenin/T cell factor-mediated transcription. Further accumulation and nuclear localization of β-catenin, and/or increased cell proliferation, was achieved by stimulation of WNT signaling with either Wnt3a, LiCl, or the constitutively active S33Y mutant of β-catenin. In contrast, by blocking WNT signaling by dominant-negative T cell factor, we can interfere with the growth of MM cells. We therefore suggest that MM cells are dependent on an active WNT signal, which may have important implications for the management of this incurable form of cancer.

Bibliography

Derksen, P. W. B., Tjin, E., Meijer, H. P., Klok, M. D., Mac Gillavry, H. D., van Oers, M. H. J., Lokhorst, H. M., Bloem, A. C., Clevers, H., Nusse, R., van der Neut, R., Spaargaren, M., & Pals, S. T. (2004). Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proceedings of the National Academy of Sciences, 101(16), 6122–6127.

Authors 13
  1. Patrick W. B. Derksen (first)
  2. Esther Tjin (additional)
  3. Helen P. Meijer (additional)
  4. Melanie D. Klok (additional)
  5. Harold D. Mac Gillavry (additional)
  6. Marinus H. J. van Oers (additional)
  7. Henk M. Lokhorst (additional)
  8. Andries C. Bloem (additional)
  9. Hans Clevers (additional)
  10. Roel Nusse (additional)
  11. Ronald van der Neut (additional)
  12. Marcel Spaargaren (additional)
  13. Steven T. Pals (additional)
References 48 Referenced 256
  1. 10.1038/nrc746
  2. 10.1182/blood.V99.4.1405
  3. 10.1016/0092-8674(82)90409-3
  4. 10.1016/S0092-8674(00)00122-7
  5. 10.1101/gad.14.15.1837
  6. 10.1016/S0092-8674(00)81333-1
  7. 10.1038/374070a0
  8. 10.1016/S1074-7613(00)00004-2
  9. 10.1016/S0092-8674(02)01014-0
  10. 10.1038/nature01593
  11. 10.1146/annurev.cellbio.14.1.59
  12. 10.1126/science.1071549
  13. 10.1016/S0092-8674(00)80112-9
  14. 10.1038/382638a0
  15. 10.1038/18884
  16. 10.1126/science.281.5382.1509
  17. 10.1016/S0002-9440(10)65297-2
  18. Boon, E. M., Van der Neut, R., van de Wetering, M., Clevers, H. & Pals, S. T. (2002) Cancer Res. 62, 5126-5128.12234972 / Cancer Res. (2002)
  19. 10.1101/gad.5.5.880
  20. 10.1002/j.1460-2075.1991.tb07928.x
  21. 10.1101/gad.5.4.656
  22. 10.1016/S0092-8674(02)00702-X
  23. Schilham, M. W., Wilson, A., Moerer, P., Benaissa-Trouw, B. J., Cumano, A. & Clevers, H. C. (1998) J. Immunol. 161, 3984-3991.9780167 (10.4049/jimmunol.161.8.3984) / J. Immunol. (1998)
  24. 10.1016/S1074-7613(00)80454-9
  25. 10.1038/ni0901-863
  26. 10.1038/90623
  27. 10.1093/embo-reports/kvf002
  28. 10.1074/jbc.M111635200
  29. 10.1182/blood.V83.12.3654.3654
  30. 10.1016/S0165-4608(98)00157-5
  31. 10.1007/BF01000590
  32. 10.1182/blood.V67.6.1542.1542
  33. 10.1002/ijc.2910360217
  34. 10.1046/j.1365-2443.1998.00221.x
  35. 10.1038/nature01611
  36. 10.1016/S0092-8674(00)81925-X
  37. 10.1126/science.275.5307.1784
  38. Koopman, G., Keehnen, R. M., Lindhout, E., Newman, W., Shimizu, Y., van Seventer, G. A., de Groot, C. & Pals, S. T. (1994) J. Immunol. 152, 3760-3767.7511659 (10.4049/jimmunol.152.8.3760) / J. Immunol. (1994)
  39. 10.1084/jem.180.1.329
  40. 10.1016/S0960-9822(02)70790-2
  41. Rohrer, J. W., Vasa, K. & Lynch, R. G. (1977) J. Immunol. 119, 861-866.330758 (10.4049/jimmunol.119.3.861) / J. Immunol. (1977)
  42. 10.1182/blood.V89.10.3624.3624_3624_3635
  43. 10.1182/blood.V92.9.3189.421k45_3189_3202
  44. 10.1073/pnas.96.20.11464
  45. 10.1038/sj.onc.1206239
  46. 10.1182/blood.V91.1.3.3_3_21
  47. 10.1182/blood.V99.5.1745
  48. 10.1038/sj.leu.2402875
Dates
Type When
Created 21 years, 4 months ago (April 5, 2004, 8:54 p.m.)
Deposited 2 years, 4 months ago (April 28, 2023, 2:46 a.m.)
Indexed 5 minutes ago (Sept. 3, 2025, 6:48 a.m.)
Issued 21 years, 4 months ago (April 5, 2004)
Published 21 years, 4 months ago (April 5, 2004)
Published Online 21 years, 4 months ago (April 5, 2004)
Published Print 21 years, 4 months ago (April 20, 2004)
Funders 0

None

@article{Derksen_2004, title={Illegitimate WNT signaling promotes proliferation of multiple myeloma cells}, volume={101}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.0305855101}, DOI={10.1073/pnas.0305855101}, number={16}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Derksen, Patrick W. B. and Tjin, Esther and Meijer, Helen P. and Klok, Melanie D. and Mac Gillavry, Harold D. and van Oers, Marinus H. J. and Lokhorst, Henk M. and Bloem, Andries C. and Clevers, Hans and Nusse, Roel and van der Neut, Ronald and Spaargaren, Marcel and Pals, Steven T.}, year={2004}, month=apr, pages={6122–6127} }